Consolidated Planning Corp Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

view original post

Consolidated Planning Corp lessened its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 2.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 4,070 shares of the company’s stock after selling 86 shares during the quarter. Johnson & Johnson comprises about 0.5% of Consolidated Planning Corp’s portfolio, making the stock its 24th largest holding. Consolidated Planning Corp’s holdings in Johnson & Johnson were worth $721,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Riversedge Advisors LLC grew its holdings in Johnson & Johnson by 8.6% during the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock worth $627,000 after acquiring an additional 289 shares during the period. Costello Asset Management INC grew its holdings in Johnson & Johnson by 13.2% during the fourth quarter. Costello Asset Management INC now owns 45,213 shares of the company’s stock worth $7,735,000 after acquiring an additional 5,262 shares during the period. Schubert & Co acquired a new position in Johnson & Johnson during the fourth quarter worth $388,000. Amplius Wealth Advisors LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $1,810,000. Finally, Berkshire Bank grew its holdings in Johnson & Johnson by 2.0% during the fourth quarter. Berkshire Bank now owns 14,129 shares of the company’s stock worth $2,417,000 after acquiring an additional 281 shares during the period. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on JNJ shares. Wells Fargo & Company upped their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th. Citigroup lowered their target price on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Credit Suisse Group upped their target price on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Morgan Stanley upped their target price on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Finally, Daiwa Capital Markets assumed coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE:JNJ opened at $174.52 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The stock’s fifty day simple moving average is $175.95 and its 200-day simple moving average is $174.42. The company has a market capitalization of $459.23 billion, a P/E ratio of 25.40, a P/E/G ratio of 3.28 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the prior year, the business earned $2.48 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Insider Buying and Selling

In related news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.